ABPI Suspends Astellas UK
The UK industry body the Association of the British Pharmaceutical Industry (ABPI) has suspended Astellas UK as a member for one year following serious breaches of its code of practice for the pharmaceutical industry.
You may also be interested in...
AstraZeneca and Genzyme have been named in advertisements for separate breaches of the Association of the British Pharmaceutical Industry's code of practice.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.